BUB1 Antibodies

Mitotic checkpoint serine/threonine-protein kinase BUB1 (BUB1)

Serine/threonine-protein kinase that performs two crucial functions during mitosis: it is essential for spindle-assembly checkpoint signaling and for correct chromosome alignment. Has a key role in the gathering of checkpoint proteins at the kinetochore, needing the subsequent localization of CENPF, BUB1B, CENPE and MAD2L1.

Required for the kinetochore localization of PLK1. Required for centromeric enrichment of AUKRB in prometaphase.

Gene Information

Human
Gene Name:	BUB1
Uniprot:	O43683
Entrez:	699

Family

Belongs to:
protein kinase superfamily

Alternative Names

BUB1 budding uninhibited by benzimidazoles 1 homolog; Bub1; BUB1Amitotic checkpoint serine/threonine-protein kinase BUB1; BUB1L; budding uninhibited by benzimidazoles 1 (yeast homolog); budding uninhibited by benzimidazoles 1 homolog (yeast); EC 2.7.11.1; hBUB1mitotic spindle checkpoint kinase; putative serine/threonine-protein kinase

Molecular Weight

Mass (kDA):
122.375 kDA

Genomic Context

Human
Location:	2q13
Sequence:	2; NC_000002.12 (110637528..110678107, complement)

Tissue Specificity

High expression in testis and thymus, less in colon, spleen, lung and small intestine. Expressed in fetal thymus, bone marrow, heart, liver, spleen and thymus. Expression is associated with cells/tissues with a high mitotic index.

Subcellular Localizations

Nucleus. Chromosome, centromere, kinetochore. Nuclear in interphase cells. Accumulates gradually during G1 and S phase of the cell cycle, peaks at G2/M, and drops dramatically after mitosis. Localizes to the outer kinetochore. Kinetochore localization is required for normal mitotic timing and checkpoint response to spindle damage and occurs very early in prophase. AURKB, KNL1 and INCENP are required for kinetochore localization (By similarity).

Diseases

• Malignant Neoplasms
• Neoplasms
• Aneuploidy
• Cell Transformation, Neoplastic
• Carcinoma
• Instabilities, Chromosomal
• Genomic Instability
• Adenocarcinoma
• Colorectal Cancer
• Cytogenetic Abnormality
• Malignant Neoplasm Of Breast
• Mammary Neoplasms
• Polyploidy

• Malignant Paraganglionic Neoplasm
• Carcinogenesis
• Leukemia
• Stomach Neoplasms
• Malignant Neoplasm Of Stomach
• Lymphoma
• Lung Neoplasms

Interacting Proteins

• ARIH2
• BUB3
• KNL1

Pathways

• Spindle Checkpoint
• Mitosis
• Anaphase
• Spindle Assembly
• Cell Cycle
• Spindle Assembly Checkpoint
• Chromosome Segregation
• Localization
• Metaphase
• Kinetochore Localization
• Meiosis
• Cell Division
• Interphase

• Rna Interference
• Cell Proliferation
• Cell Death
• Cytokinesis
• Sister Chromatid Cohesion
• Cell Cycle Arrest
• Prophase

PTMs

• Phosphorylation
• Cleavage
• Dephosphorylation

• Ubiquitination
• Acetylation
• Methylation

Research Areas

• Breast Cancer
• Cell Cycle and Replication
• Core ESC-Like Genes
• Mitotic Regulators
• Stem Cell Markers

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/BUB1

Best Uses of the BUB1 Marker

If you are a scientist, you have probably been wondering about what Boster Bio is and what it does for you. We will talk about the most common uses for the BUB1 marker in Gastric Adenocarcinoma and Cervical cancer. Additionally, we will examine ways to capture boster proteins using chromatography techniques typically used for conventional chromatography.

GC

Recent research suggests that BUB1 may help predict the response to cell cycle kinase inhibitors in clinical trials of GC. This marker could be used for identifying patients who are likely to benefit from antiproliferative or checkpoint chemotherapy drugs. However the BUB1 marker is associated with significant side negative effects. In addition to its diagnostic use, BUB1 expression has been suggested to help identify new therapeutic targets for GC.

The BUB1 marker has been linked with improved prognosis in certain patients suffering from GC. Recent studies have compared BUB1 expression levels in patients with early-stage GC and those with advanced stages. Patients with low levels of BUB1 expression were associated with a lower prognosis. The BUB1 gene is present in different types of cancer such as diffuse and tubular however it was not associated with poor prognosis for patients with a more advanced stage.

43 genes were identified in the study that are related to CSC characteristics in DGC and IGC. Certain of these genes are linked to the cell cycle, which might serve as a therapeutic target for stem cell inhibition. The BUB1 gene was also associated with the expression of genes involved in the cycle of cells in both types of GC. This marker could be used to detect cancer cells earlier. This marker could also be used to detect GC in women.

The BUB1 gene is expressed at high levels in lung adenocarcinomas compared to healthy tissue. However, the BUB1 gene expression level varies according to a patient's genetic profile. The BUB1 gene has been found to be a significant molecular marker for lung adenocarcinoma. The most reliable predictors of lung cancer have been identified as markers RBX1 and BUB1.

Adenocarcinoma gastric

The low prognosis for gastric cancer and the poor prognosis have been linked to high levels of BUB1 protein. The high levels of BUB1 protein are associated with larger tumors as well as higher UICC stages, and lymph node metastasis. It is also associated with lower levels of residual tumor stage. A high amount of BUB1 expression is linked to a poor prognosis and the frequent expression of Ki-67.

BUB1 is observed to be overexpressed in DGC and IGC, and is more connected in PPI networks. BUB1 is linked to the development of tumors, metastasis and progression. It is gradually accumulated in the G2 / M phase and plays a crucial role in cell division. Inhibition of BUB1 can decrease the growth of tumors by promoting cell apoptosis. It is also involved with the TGF/Smad pathway.

However, BUB1 expression in stomach cancer isn't fully understood. Numerous studies have proven that BUB1 expression in stomach cancer is linked to poor prognosis. However, some studies have demonstrated that there is a link between BUB1 and positive prognosis. In other types of cancer the presence of high BUB1 expression is associated with an unfavorable prognosis.

A number of studies have also investigated the relationship between BUB1 expression and gastric adenocarcinoma prognosis. Cho et al. looked into gastric cancer and normal gastric tissue. Their findings support the association between BUB1 expression and GC risk. These findings suggest a new therapeutic approach to treat gastric cancer.

The results of RNA sequencing showed an important difference in the expression of tumors and normal gastric tissue. More than 600 genes displayed different expression. A total of 6685 DEGs were identified, of which 5479 were upregulated , and 1206 were downregulated. The results of this study were mapped using the pheatmap package. The genes with the highest levels of upregulation were identified. The remaining genes were verified by measuring gene expression.

Breast cancer

In this study, BUB1 was found to be significantly more prevalent in tumors than in normal bladder epithelium. Additionally, its expression increased with the progression of bladder cancer. This suggests that BUB1 could play a part in the development of bladder cancer. Although further research is needed to understand the exact mechanism behind BUB1 involvement, it is possible to focus on this gene as a treatment option. We will discuss the most recent findings regarding BUB1 immunohistochemical staining to detect bladder cancer.

To assess the transcriptionomes in the breast cancer cells, RNA sequencing was performed on 5637 cells. We discovered that BUB1 altered the expression levels of a variety of genes involved in cell adhesion as well as the positive regulation of JAK-STAT signaling. We also discovered that BUB1 downregulation increased the expression of 1697 genes while decreasing the expression of 1246.

This study included 176 samples of males, which included 76. The median age was 47 years, and the range was 19-83 years. We also observed that levels of mRNA expression for malignant PCC/PGLs was significantly higher than normal tissues and linked to five distinct pathways, including calcium signaling and the actin cytoskeleton. We also observed that high expression levels of BUB1 were associated with lower mortality rates in patients with no disease.

We also found that BUB1 levels were significantly linked to histological grade as well as low mismatch repair parameters and histological grade. We also discovered that BUB1B amplifying wasn't detected in tumor samples that were analyzed using array-based comparative genome hybridization. Despite the absence of BUB1B amplifying in tumor samples high copy numbers were associated with overexpression of BUB1B. Insufficient MSH2 levels, lymphovascular invasion and stage of pathological tumors were all significant factors in the longevity of disease-specific patients.

Cervical cancer

Recent research suggests that BUB1 may be a biomarker for cervical carcinoma. Further research is required to confirm the diagnostic function of BUB1. It could be one of the most significant cervical cancer markers for cytogenetics. Researchers are currently studying the effects of BUB1 on the growth of tumors, metastasis and survival. The most effective uses for the BUB1 marker in cervical cancer include determining its amplification status and identifying cancer-related genes.

The BUB1 gene encodes a protein called BUBR1. The protein is essential for the checkpoint that is required in spindle assembly. Recessive mosaic variegated aneuploidy syndrome is a genetic predisposition to cancer. Variations in BUB1 could cause recessive mosaic aneuploidy that is variable. Gingival neoplasms, as well as cancer are associated with low levels of wild-type BUB1 proteins. Researchers used next-generation sequencing which was amplicon-based to identify BUB1 mutations in germline DNA in the 192 patients.

BUB1 gene expression was associated with poor overall survival and a low rate of disease-free survival. Its expression was enriched in several pathways, including glycolysis/gluconeogenesis, DNA replication, and cell cycle signaling pathways. These genes may be useful as diagnostic markers, but their molecular basis remains unclear. As of now, these studies suggest that BUB1 could be a useful diagnostic tool for cervical cancer.

Oncomine also demonstrates that the BUB1 gene is associated with the grade of cancer. Genes that express the BUB1 gene in cervical cancer were significantly associated with the grade of tumors and the signaling pathway p53. This gene could predict cervical cancer progression. While there are many other uses for BUB1 genes, the BUB1 Gene is utilized as an indicator for cervical carcinoma.

Pancreatic cancer

Boster Bio researchers published recent findings suggesting that the BUB1 marker may be a useful tool in forecasting the prognosis of GC patients. BUB1 is present in both GC tumors and normal pancreatic tissue. Patients with lower levels BUB1 expression were more likely to suffer worse outcomes. The BUB1 gene was only present in only 1% of pancreatic tumor patients.

The BUB1 marker was recently verified in two sets blood samples. The 432 samples tested were from pancreatic cancer. The biomarkers were assessed individually for their effectiveness in the distinction of PDAC from the control group. Multiparametric modeling was used to determine the capacity of marker panels to differentiate between PDAC and healthy controls. Models were created and tested using the Sample Set B and the Sample Set A.

The BUB1 gene belongs to a class of genes referred to as Lysyl-oxidases. It is located on the surface of cells as well as in the endoplasmic retina. Although its role in normal human structures remains undetermined but it has been associated in various cancers, including pancreatic cancer. Additionally, it is associated with posttranscriptional regulation of the cathepsins and D.

The pancreatic acinar-granules contain a high amount of the BUB1 marker. It has a role in the maturation and the transport of Zymogens. It also regulates the function of neutrophils as well as the cell in the HL-60 cell. It was also found to be elevated in serum from patients with murine pancreatic carcinoma. Biomarkers that are developed in the future will allow for the identification of subgroups of patients and optimization of treatment.